---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007878"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:47:51.869032+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q1 net loss narrows to $12.7M; Checkpoint acquisition on track

## Summary
- Consolidated net loss $12.7M ($0.48/sh) vs $17.9M ($1.04/sh) in Q1 2024.
- Cash $91.3M as of March 31, 2025, up $34.0M from Dec 2024; Checkpoint holds $33.0M.
- Emrosi launched in March 2025; first prescriptions filled for inflammatory rosacea lesions.
- Checkpoint to be acquired by Sun Pharma for $4.10/sh plus $0.70 CVR; Fortress expects ~$28M at closing.
- CUTX-101 NDA priority review with PDUFA Sept 30, 2025; Cyprium retains 100% of any PRV.

## SEC filing metadata
- accession: 0001558370-25-007878
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/0001558370-25-007878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007878
- JSON: https://secwatch.observer/filing/0001558370-25-007878.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.